These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 11016962)

  • 81. Research progress of interleukin-15 in cancer immunotherapy.
    Cai M; Huang X; Huang X; Ju D; Zhu YZ; Ye L
    Front Pharmacol; 2023; 14():1184703. PubMed ID: 37251333
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Predicting the Progress of Tuberculosis by Inflammatory Response-Related Genes Based on Multiple Machine Learning Comprehensive Analysis.
    Ma S; Peng P; Duan Z; Fan Y; Li X
    J Immunol Res; 2023; 2023():7829286. PubMed ID: 37228444
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The role of interleukin-15 in the development and treatment of hematological malignancies.
    Sindaco P; Pandey H; Isabelle C; Chakravarti N; Brammer JE; Porcu P; Mishra A
    Front Immunol; 2023; 14():1141208. PubMed ID: 37153603
    [TBL] [Abstract][Full Text] [Related]  

  • 84. An updated profile of the bovine acute phase response following an intravenous lipopolysaccharide challenge.
    Smock TM; Rand Broadway P; Burdick Sanchez NC; Carroll JA; Theurer ME; Hales KE
    J Anim Sci; 2023 Jan; 101():. PubMed ID: 37115605
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The application of Interleukin-2 family cytokines in tumor immunotherapy research.
    Zhou Y; Quan G; Liu Y; Shi N; Wu Y; Zhang R; Gao X; Luo L
    Front Immunol; 2023; 14():1090311. PubMed ID: 36936961
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Long-lived autoreactive memory CD4
    Fan NW; Zhu Q; Wang S; Ortiz G; Huckfeldt RM; Chen Y
    FASEB J; 2023 Apr; 37(4):e22855. PubMed ID: 36906286
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy.
    Liu Z; Shi M; Ren Y; Xu H; Weng S; Ning W; Ge X; Liu L; Guo C; Duo M; Li L; Li J; Han X
    Mol Cancer; 2023 Feb; 22(1):35. PubMed ID: 36797756
    [TBL] [Abstract][Full Text] [Related]  

  • 88. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
    Wong JL; Smith P; Angulo-Lozano J; Ranti D; Bochner BH; Sfakianos JP; Horowitz A; Ravetch JV; Knorr DA
    bioRxiv; 2023 Feb; ():. PubMed ID: 36778311
    [TBL] [Abstract][Full Text] [Related]  

  • 89. INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses.
    Sulzmaier FJ; Kern N; Ahn SJ; Polovina A; Ho J; Hussain A; Cyprus G; Macedo C; Pandit R; Crago W; Rowell E; Timmer JC; Eckelman BP
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36653071
    [TBL] [Abstract][Full Text] [Related]  

  • 90. SOT101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity.
    Antosova Z; Podzimkova N; Tomala J; Augustynkova K; Sajnerova K; Nedvedova E; Sirova M; de Martynoff G; Bechard D; Moebius U; Kovar M; Spisek R; Adkins I
    Front Immunol; 2022; 13():989895. PubMed ID: 36300122
    [TBL] [Abstract][Full Text] [Related]  

  • 91. A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities.
    Lv L; Wang H; Shi W; Wang Y; Zhu W; Liu Z; Chen X; Zheng C; Kong W; Li W; Zhu J; Lu H
    Appl Microbiol Biotechnol; 2022 Nov; 106(21):7039-7050. PubMed ID: 36184689
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity.
    Shi W; Lv L; Liu N; Wang H; Wang Y; Zhu W; Liu Z; Zhu J; Lu H
    Mol Ther; 2023 Jan; 31(1):66-77. PubMed ID: 36045584
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Next Generation Natural Killer Cells for Cancer Immunotherapy.
    Rossi F; Fredericks N; Snowden A; Allegrezza MJ; Moreno-Nieves UY
    Front Immunol; 2022; 13():886429. PubMed ID: 35720306
    [TBL] [Abstract][Full Text] [Related]  

  • 94. IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors.
    Chen W; Bamford RN; Edmondson EF; Waldmann TA
    Clin Cancer Res; 2022 May; 28(10):2082-2093. PubMed ID: 35262675
    [TBL] [Abstract][Full Text] [Related]  

  • 95. A very long-acting IL-15: implications for the immunotherapy of cancer.
    Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
    [TBL] [Abstract][Full Text] [Related]  

  • 96. In vivo availability of the cytokine IL-7 constrains the survival and homeostasis of peripheral iNKT cells.
    Park JY; Won HY; DiPalma DT; Kim HK; Kim TH; Li C; Sato N; Hong C; Abraham N; Gress RE; Park JH
    Cell Rep; 2022 Jan; 38(2):110219. PubMed ID: 35021100
    [TBL] [Abstract][Full Text] [Related]  

  • 97. IL-15Rα-Independent IL-15 Signaling in Non-NK Cell-Derived IFNγ Driven Control of
    Nandi M; Moyo MM; Orkhis S; Mobulakani JMF; Limoges MA; Rexhepi F; Mayhue M; Cayarga AA; Marrero GC; Ilangumaran S; Menendez A; Ramanathan S
    Front Immunol; 2021; 12():793918. PubMed ID: 34956227
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
    Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
    Front Immunol; 2021; 12():732135. PubMed ID: 34925314
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors.
    Conlon K; Watson DC; Waldmann TA; Valentin A; Bergamaschi C; Felber BK; Peer CJ; Figg WD; Potter EL; Roederer M; McNeel DG; Thompson JA; Gupta S; Leidner R; Wang-Gillam A; Parikh NS; Long D; Kurtulus S; Ho Lee L; Chowdhury NR; Bender F; Pavlakis GN
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34799399
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.
    Ghahri-Saremi N; Akbari B; Soltantoyeh T; Hadjati J; Ghassemi S; Mirzaei HR
    Front Immunol; 2021; 12():738456. PubMed ID: 34721401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.